The Role of Astrocytes in Parkinson's Disease : Astrocytes in Parkinson's Disease.
Blood–brain barrier
Calcium signaling
Heterogeneity
Neurodegeneration
Neuroinflammation
Parkinson’s disease
α-synuclein
Journal
Advances in neurobiology
ISSN: 2190-5215
Titre abrégé: Adv Neurobiol
Pays: United States
ID NLM: 101571545
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a neurodegenerative disorder with a complex and multifactorial pathogenesis. This chapter delves into the critical role of astrocytes in PD. Once viewed as supporting cells in the central nervous system, astrocytes have emerged as key players in both maintaining neuronal health and contributing to neurodegeneration in PD. Their functions play a dual role in the progression of PD, ranging from protective functions like secretion of neurotrophic factors and clearance of α-synuclein to detrimental functions like promotion of neuroinflammation. This chapter is structured into three primary sections: the morphological and functional organization of astrocytes, astrocytic calcium signaling, and the role of astrocyte heterogeneity in PD. We provide a detailed exploration of astrocytic organelles, bidirectional astrocyte-neuron interactions, and the impact of astrocytic secretions such as antioxidant molecules and neurotrophic factors. Furthermore, we discuss the influence of astrocytes on non-neuronal cells, including interactions with microglia and the blood-brain barrier (BBB). By examining the multifaceted roles of astrocytes, in this chapter, we aim to bridge basic astrocyte biology with the clinical complexities of PD, offering insights into novel therapeutic strategies. The inclusion of astrocyte biology in our broader research approach will aid in the development of more effective treatment strategies for PD.
Identifiants
pubmed: 39190081
doi: 10.1007/978-3-031-64839-7_13
doi:
Substances chimiques
Nerve Growth Factors
0
alpha-Synuclein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-343Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
pubmed: 28332488
doi: 10.1038/nrdp.2017.13
Stocchi F, Vacca L, Radicati FG. How to optimize the treatment of early stage Parkinson’s disease. Transl Neurodegener. 2015;4(1):4.
pubmed: 25973179
pmcid: 4429368
doi: 10.1186/2047-9158-4-4
Booth HDE, Hirst WD, Wade-Martins R. The role of astrocyte dysfunction in Parkinson’s disease pathogenesis. Trends Neurosci. 2017;40(6):358–70.
pubmed: 28527591
pmcid: 5462417
doi: 10.1016/j.tins.2017.04.001
Baldwin KT, Murai KK, Khakh BS. Astrocyte Morphology. Trends Cell Biol. 2023;34(7):547–565.
Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399.
pubmed: 22355802
pmcid: 3281589
doi: 10.1101/cshperspect.a009399
Loria F, Vargas JY, Bousset L, Syan S, Salles A, Melki R, Zurzolo C. α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol. 2017;134(5):789–808.
pubmed: 28725967
doi: 10.1007/s00401-017-1746-2
Ozoran H, Srinivasan R. Astrocytes and alpha-synuclein: friend or foe? J Parkinsons Dis. 2023;13:1289–301.
pubmed: 38007674
pmcid: 10741342
doi: 10.3233/JPD-230284
Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol. 2002;176(1):98–104.
pubmed: 12093086
doi: 10.1006/exnr.2002.7929
Tanji K, Imaizumi T, Yoshida H, Mori F, Yoshimoto M, Satoh K, Wakabayashi K. Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta. Neuroreport. 2001;12(9):1909–12.
pubmed: 11435921
doi: 10.1097/00001756-200107030-00028
Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285(12):9262–72.
pubmed: 20071342
pmcid: 2838344
doi: 10.1074/jbc.M109.081125
Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, et al. Astrocytes protect human dopaminergic neurons from α-synuclein accumulation and propagation. J Neurosci. 2020;40(45):8618–28.
pubmed: 33046546
pmcid: 7643299
doi: 10.1523/JNEUROSCI.0954-20.2020
Rostami J, Holmqvist S, Lindström V, Sigvardson J, Westermark GT, Ingelsson M, et al. Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci. 2017;37(49):11835–53.
pubmed: 29089438
pmcid: 5719970
doi: 10.1523/JNEUROSCI.0983-17.2017
Rostami J, Mothes T, Kolahdouzan M, Eriksson O, Moslem M, Bergström J, et al. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. J Neuroinflammation. 2021;18(1):124.
pubmed: 34082772
pmcid: 8173980
doi: 10.1186/s12974-021-02158-3
Venturini A, Passalacqua M, Pelassa S, Pastorino F, Tedesco M, Cortese K, et al. Exosomes from astrocyte processes: signaling to neurons. Front Pharmacol. 2019;10:1452.
pubmed: 31849688
pmcid: 6901013
doi: 10.3389/fphar.2019.01452
Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30(20):6838–51.
pubmed: 20484626
pmcid: 3842464
doi: 10.1523/JNEUROSCI.5699-09.2010
Chou TW, Chang NP, Krishnagiri M, Patel AP, Lindman M, Angel JP, et al. Fibrillar α-synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF-κB. Cell Death Dis. 2021;12(8):756.
pubmed: 34333522
pmcid: 8325686
doi: 10.1038/s41419-021-04049-0
Russ K, Teku G, Bousset L, Redeker V, Piel S, Savchenko E, et al. TNF-α and α-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration. Cell Rep. 2021;34(12):108895.
pubmed: 33761362
doi: 10.1016/j.celrep.2021.108895
Navarro-Romero A, Montpeyó M, Martinez-Vicente M. The emerging role of the lysosome in Parkinson’s disease. Cells. 2020;9(11):2399.
pubmed: 33147750
pmcid: 7692401
doi: 10.3390/cells9112399
Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27.
pubmed: 30275469
doi: 10.1038/s41572-018-0025-4
Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E. A characterization of Gaucher iPS-derived astrocytes: potential implications for Parkinson’s disease. Neurobiol Dis. 2020;134:104647.
pubmed: 31669751
doi: 10.1016/j.nbd.2019.104647
Henry AG, Aghamohammadzadeh S, Samaroo H, Chen Y, Mou K, Needle E, Hirst WD. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum Mol Genet. 2015;24(21):6013–28.
pubmed: 26251043
doi: 10.1093/hmg/ddv314
Bose A, Beal MF. Mitochondrial dysfunction in Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):216–31.
pubmed: 27546335
doi: 10.1111/jnc.13731
Larsen NJ, Ambrosi G, Mullett SJ, Berman SB, Hinkle DA. DJ-1 knock-down impairs astrocyte mitochondrial function. Neuroscience. 2011;196:251–64.
pubmed: 21907265
doi: 10.1016/j.neuroscience.2011.08.016
Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain. 2004;127(Pt 2):420–30.
pubmed: 14662519
doi: 10.1093/brain/awh054
Vincent BM, Tardiff DF, Piotrowski JS, Aron R, Lucas MC, Chung CY, et al. Inhibiting stearoyl-CoA desaturase ameliorates α-synuclein cytotoxicity. Cell Rep. 2018;25(10):2742–54.e31.
pubmed: 30517862
doi: 10.1016/j.celrep.2018.11.028
Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, et al. Lipidomic analysis of α-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment. Mol Cell. 2019;73(5):1001–14.e8.
pubmed: 30527540
doi: 10.1016/j.molcel.2018.11.028
Ioannou MS, Jackson J, Sheu SH, Chang CL, Weigel AV, Liu H, et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell. 2019;177(6):1522–35.e14.
pubmed: 31130380
doi: 10.1016/j.cell.2019.04.001
Bantle CM, Hirst WD, Weihofen A, Shlevkov E. Mitochondrial dysfunction in astrocytes: a role in Parkinson’s disease? Front Cell Dev Biol. 2020;8:608026.
pubmed: 33537300
doi: 10.3389/fcell.2020.608026
Joshi AU, Minhas PS, Liddelow SA, Haileselassie B, Andreasson KI, Dorn GW 2nd, Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat Neurosci. 2019;22(10):1635–48.
pubmed: 31551592
pmcid: 6764589
doi: 10.1038/s41593-019-0486-0
Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization. Nat Chem Biol. 2006;2(5):249–53.
pubmed: 16565714
doi: 10.1038/nchembio782
Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res. 2007;85(5):919–34.
pubmed: 17279544
doi: 10.1002/jnr.21191
Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461–91.
pubmed: 24252804
pmcid: 4135313
doi: 10.3233/JPD-130230
Miyazaki I, Asanuma M. Neuron-astrocyte interactions in Parkinson’s disease. Cells. 2020;9(12):2623.
pubmed: 33297340
pmcid: 7762285
doi: 10.3390/cells9122623
Kranich O, Hamprecht B, Dringen R. Different preferences in the utilization of amino acids for glutathione synthesis in cultured neurons and astroglial cells derived from rat brain. Neurosci Lett. 1996;219(3):211–4.
pubmed: 8971817
doi: 10.1016/S0304-3940(96)13217-1
Wang XF, Cynader MS. Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem. 2000;74(4):1434–42.
pubmed: 10737599
doi: 10.1046/j.1471-4159.2000.0741434.x
Dringen R, Gutterer JM, Gros C, Hirrlinger J. Aminopeptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons. J Neurosci Res. 2001;66(5):1003–8.
pubmed: 11746430
doi: 10.1002/jnr.10042
Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, et al. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 2003;24(3):159–60.
pubmed: 14598065
doi: 10.1007/s10072-003-0108-0
Neves M, Grãos M, Anjo SI, Manadas B. Modulation of signaling pathways by DJ-1: an updated overview. Redox Biol. 2022;51:102283.
pubmed: 35303520
pmcid: 8928136
doi: 10.1016/j.redox.2022.102283
Hayes JD, Chanas SA, Henderson CJ, McMahon M, Sun C, Moffat GJ, et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem Soc Trans. 2000;28(2):33–41.
pubmed: 10816095
doi: 10.1042/bst0280033
Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci. 2003;23(8):3394–406.
pubmed: 12716947
pmcid: 6742304
doi: 10.1523/JNEUROSCI.23-08-03394.2003
Engele J, Bohn MC. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. J Neurosci. 1991;11(10):3070–8.
pubmed: 1941074
pmcid: 6575454
doi: 10.1523/JNEUROSCI.11-10-03070.1991
Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 2007;448(7149):73–7.
pubmed: 17611540
doi: 10.1038/nature05957
Voutilainen MH, Bäck S, Pörsti E, Toppinen L, Lindgren L, Lindholm P, et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson’s disease. J Neurosci. 2009;29(30):9651–9.
pubmed: 19641128
pmcid: 6666534
doi: 10.1523/JNEUROSCI.0833-09.2009
Lindholm P, Saarma M. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol Psychiatry. 2022;27(3):1310–21.
pubmed: 34907395
doi: 10.1038/s41380-021-01394-6
Duarte Azevedo M, Sander S, Tenenbaum L. GDNF, a neuron-derived factor upregulated in glial cells during disease. J Clin Med. 2020;9(2):456.
pubmed: 32046031
pmcid: 7073520
doi: 10.3390/jcm9020456
Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, et al. S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain. 2012;135(11):3336–47.
pubmed: 23169921
pmcid: 3501971
doi: 10.1093/brain/aws250
Bancroft EA, De La Mora M, Pandey G, Zarate SM, Srinivasan R. Extracellular S100B inhibits A-type voltage-gated potassium currents and increases L-type voltage-gated calcium channel activity in dopaminergic neurons. Glia. 2022;70(12):2330–47.
pubmed: 35916350
pmcid: 10738449
doi: 10.1002/glia.24254
Verma A, Ravindranath V. CaV1.3 L-type calcium channels increase the vulnerability of substantia Nigra dopaminergic neurons in MPTP mouse model of Parkinson’s disease. Front Aging Neurosci. 2020;11:382.
pubmed: 32009942
pmcid: 6978652
doi: 10.3389/fnagi.2019.00382
Wang R, Ma Z, Wang J, Xie J. L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats. Neurotox Res. 2012;21(3):266–70.
pubmed: 21901331
doi: 10.1007/s12640-011-9271-x
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–7.
pubmed: 28099414
pmcid: 5404890
doi: 10.1038/nature21029
Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med. 2018;24(7):931–8.
pubmed: 29892066
pmcid: 6039259
doi: 10.1038/s41591-018-0051-5
Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, Zheng H. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer’s disease. J Neurosci. 2016;36(2):577–89.
pubmed: 26758846
pmcid: 4710776
doi: 10.1523/JNEUROSCI.2117-15.2016
Cabezas R, Avila M, Gonzalez J, El-Bachá RS, Báez E, García-Segura LM, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front Cell Neurosci. 2014;8:211.
pubmed: 25136294
pmcid: 4120694
doi: 10.3389/fncel.2014.00211
Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia. 1997;19(1):13–26.
pubmed: 8989564
doi: 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B
Abbott NJ, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.
pubmed: 16371949
doi: 10.1038/nrn1824
Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci. 2005;22(5):1158–68.
pubmed: 16176358
doi: 10.1111/j.1460-9568.2005.04281.x
Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson’s disease. J Cereb Blood Flow Metab. 2015;35(5):747–50.
pubmed: 25757748
pmcid: 4420870
doi: 10.1038/jcbfm.2015.32
de Rus JA, Alpaugh M, Denis HL, Tancredi JL, Boutin M, Decaestecker J, et al. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease. Nat Commun. 2023;14(1):3651.
doi: 10.1038/s41467-023-39038-8
Bancroft EA, Srinivasan R. Emerging roles for aberrant astrocytic calcium signals in Parkinson’s disease. Front Physiol. 2022;12:812212.
pubmed: 35087422
pmcid: 8787054
doi: 10.3389/fphys.2021.812212
Semyanov A, Henneberger C, Agarwal A. Making sense of astrocytic calcium signals – from acquisition to interpretation. Nat Rev Neurosci. 2020;21(10):551–64.
pubmed: 32873937
doi: 10.1038/s41583-020-0361-8
Okubo Y, Kanemaru K, Suzuki J, Kobayashi K, Hirose K, Iino M. Inositol 1,4,5-trisphosphate receptor type 2-independent Ca(2+) release from the endoplasmic reticulum in astrocytes. Glia. 2019;67(1):113–24.
pubmed: 30306640
doi: 10.1002/glia.23531
Huntington TE, Srinivasan R. Astrocytic mitochondria in adult mouse brain slices show spontaneous calcium influx events with unique properties. Cell Calcium. 2021;96:102383.
pubmed: 33676316
doi: 10.1016/j.ceca.2021.102383
Srinivasan R, Huang BS, Venugopal S, Johnston AD, Chai H, Zeng H, et al. Ca(2+) signaling in astrocytes from Ip3r2(-/-) mice in brain slices and during startle responses in vivo. Nat Neurosci. 2015;18(5):708–17.
pubmed: 25894291
pmcid: 4429056
doi: 10.1038/nn.4001
Lewerenz J, Maher P. Chronic glutamate toxicity in neurodegenerative diseases-what is the evidence? Front Neurosci. 2015;9:469.
pubmed: 26733784
pmcid: 4679930
doi: 10.3389/fnins.2015.00469
Sonnewald U, Schousboe A. Introduction to the glutamate-glutamine cycle. Adv Neurobiol. 2016;13:1–7.
pubmed: 27885624
doi: 10.1007/978-3-319-45096-4_1
Malik AR, Willnow TE. Excitatory amino acid transporters in physiology and disorders of the central nervous system. Int J Mol Sci. 2019;20(22):5671.
pubmed: 31726793
pmcid: 6888459
doi: 10.3390/ijms20225671
Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson’s disease: the role of glial cells. J Pharmacol Sci. 2020;144(3):151–64.
pubmed: 32807662
doi: 10.1016/j.jphs.2020.07.011
Kim JM, Cha SH, Choi YR, Jou I, Joe EH, Park SM. DJ-1 deficiency impairs glutamate uptake into astrocytes via the regulation of flotillin-1 and caveolin-1 expression. Sci Rep. 2016;6:28823.
pubmed: 27346864
pmcid: 4922019
doi: 10.1038/srep28823
Chotibut T, Meadows S, Kasanga EA, McInnis T, Cantu MA, Bishop C, Salvatore MF. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson’s disease model. Mov Disord. 2017;32(11):1547–56.
pubmed: 28631864
pmcid: 5681381
doi: 10.1002/mds.27077
Corkrum M, Covelo A, Lines J, Bellocchio L, Pisansky M, Loke K, et al. Dopamine-evoked synaptic regulation in the nucleus accumbens requires astrocyte activity. Neuron. 2020;105(6):1036–47.e5.
pubmed: 31954621
pmcid: 7322729
doi: 10.1016/j.neuron.2019.12.026
Xin W, Schuebel KE, Jair KW, Cimbro R, De Biase LM, Goldman D, Bonci A. Ventral midbrain astrocytes display unique physiological features and sensitivity to dopamine D2 receptor signaling. Neuropsychopharmacology. 2019;44(2):344–55.
pubmed: 30054584
doi: 10.1038/s41386-018-0151-4
Schmidt S, Linnartz B, Mendritzki S, Sczepan T, Lübbert M, Stichel CC, Lübbert H. Genetic mouse models for Parkinson’s disease display severe pathology in glial cell mitochondria. Hum Mol Genet. 2011;20(6):1197–211.
pubmed: 21212098
doi: 10.1093/hmg/ddq564
Huang X, Su Y, Wang N, Li H, Li Z, Yin G, et al. Astroglial connexins in neurodegenerative diseases. Front Mol Neurosci. 2021;14:657514.
pubmed: 34122008
pmcid: 8192976
doi: 10.3389/fnmol.2021.657514
Nielsen MS, Axelsen LN, Sorgen PL, Verma V, Delmar M, Holstein-Rathlou NH. Gap junctions. Compr Physiol. 2012;2(3):1981–2035.
pubmed: 23723031
doi: 10.1002/cphy.c110051
Giaume C, Naus CC, Sáez JC, Leybaert L. Glial connexins and pannexins in the healthy and diseased brain. Physiol Rev. 2021;101(1):93–145.
pubmed: 32326824
doi: 10.1152/physrev.00043.2018
Retamal MA, Cortés CJ, Reuss L, Bennett MV, Sáez JC. S-nitrosylation and permeation through connexin 43 hemichannels in astrocytes: induction by oxidant stress and reversal by reducing agents. Proc Natl Acad Sci USA. 2006;103(12):4475–80.
pubmed: 16537412
pmcid: 1450196
doi: 10.1073/pnas.0511118103
Retamal MA, Froger N, Palacios-Prado N, Ezan P, Sáez PJ, Sáez JC, Giaume C. Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. J Neurosci. 2007;27(50):13781–92.
pubmed: 18077690
pmcid: 6673621
doi: 10.1523/JNEUROSCI.2042-07.2007
Rufer M, Wirth S, Hofer A, Dermietzel R, Pastor A, Kettenmann H, Unsicker K. Regulation of connexin-43, GFAP, and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-lesioned, FGF-2-treated Parkisonian mice. J Neurosci Res. 1996;46(5):606–17.
pubmed: 8951672
doi: 10.1002/(SICI)1097-4547(19961201)46:5<606::AID-JNR9>3.0.CO;2-N
Maatouk L, Yi C, Carrillo-de Sauvage MA, Compagnion AC, Hunot S, Ezan P, et al. Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity. Cell Death Differ. 2019;26(3):580–96.
pubmed: 30006609
doi: 10.1038/s41418-018-0150-3
Fujita A, Yamaguchi H, Yamasaki R, Cui Y, Matsuoka Y, Yamada KI, Kira JI. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model. J Neuroinflammation. 2018;15(1):227.
pubmed: 30103794
pmcid: 6090688
doi: 10.1186/s12974-018-1251-0
Díaz EF, Labra VC, Alvear TF, Mellado LA, Inostroza CA, Oyarzún JE, et al. Connexin 43 hemichannels and pannexin-1 channels contribute to the α-synuclein-induced dysfunction and death of astrocytes. Glia. 2019;67(8):1598–619.
pubmed: 31033038
doi: 10.1002/glia.23631
Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci. 2006;9(2):260–7.
pubmed: 16388306
doi: 10.1038/nn1623
Zarate SM, Huntington TE, Bagher P, Srinivasan R. Aging reduces calreticulin expression and alters spontaneous calcium signals in astrocytic endfeet of the mouse dorsolateral striatum. NPJ Aging. 2023;9(1):5.
pubmed: 37002232
pmcid: 10066375
doi: 10.1038/s41514-023-00102-8
Hoenen C, Gustin A, Birck C, Kirchmeyer M, Beaume N, Felten P, et al. Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS One. 2016;11(9):e0162717.
pubmed: 27622765
pmcid: 5021287
doi: 10.1371/journal.pone.0162717
Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M. Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience. 2012;208:85–96.
pubmed: 22342967
doi: 10.1016/j.neuroscience.2012.02.004
Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21(2):404–12.
pubmed: 16182554
doi: 10.1016/j.nbd.2005.08.002
Sun H, Liang R, Yang B, Zhou Y, Liu M, Fang F, et al. Aquaporin-4 mediates communication between astrocyte and microglia: implications of neuroinflammation in experimental Parkinson’s disease. Neuroscience. 2016;317:65–75.
pubmed: 26774050
doi: 10.1016/j.neuroscience.2016.01.003
Kitchen P, Salman MM, Halsey AM, Clarke-Bland C, MacDonald JA, Ishida H, et al. Targeting aquaporin-4 subcellular localization to treat central nervous system edema. Cell. 2020;181(4):784–99.e19.
pubmed: 32413299
pmcid: 7242911
doi: 10.1016/j.cell.2020.03.037
Salman MM, Kitchen P, Woodroofe MN, Brown JE, Bill RM, Conner AC, Conner MT. Hypothermia increases aquaporin 4 (AQP4) plasma membrane abundance in human primary cortical astrocytes via a calcium/transient receptor potential vanilloid 4 (TRPV4)- and calmodulin-mediated mechanism. Eur J Neurosci. 2017;46(9):2542–7.
pubmed: 28925524
pmcid: 5765450
doi: 10.1111/ejn.13723
Chai H, Diaz-Castro B, Shigetomi E, Monte E, Octeau JC, Yu X, et al. Neural circuit-specialized astrocytes: transcriptomic, proteomic, morphological, and functional evidence. Neuron. 2017;95(3):531–549.e9.
pubmed: 28712653
pmcid: 5811312
doi: 10.1016/j.neuron.2017.06.029
Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson’s disease. Neurochem Int. 2019;126:1–10.
pubmed: 30825602
doi: 10.1016/j.neuint.2019.02.019
Bondi H, Chiazza F, Masante I, Bortolotto V, Canonico PL, Grilli M. Heterogenous response to aging of astrocytes in murine substantia Nigra pars compacta and pars reticulata. Neurobiol Aging. 2023;123:23–34.
pubmed: 36630756
doi: 10.1016/j.neurobiolaging.2022.12.010
Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24(3):312–25.
pubmed: 33589835
pmcid: 8007081
doi: 10.1038/s41593-020-00783-4
Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32(18):6391–410.
pubmed: 22553043
pmcid: 3480225
doi: 10.1523/JNEUROSCI.6221-11.2012
Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Yera D, et al. IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. Cell Death Dis. 2011;2(4):e142.
pubmed: 21472005
pmcid: 3122054
doi: 10.1038/cddis.2011.17
Soreq L, Rose J, Soreq E, Hardy J, Trabzuni D, Cookson MR, et al. Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. Cell Rep. 2017;18(2):557–70.
pubmed: 28076797
pmcid: 5263238
doi: 10.1016/j.celrep.2016.12.011
Yang Y, Song J-J, Choi YR, Kim S-H, Seok M-J, Wulansari N, et al. Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease. Proc Natl Acad Sci. 2022;119(29):e2110746119.
pubmed: 35858361
pmcid: 9304026
doi: 10.1073/pnas.2110746119
Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589–95.
pubmed: 12669033
doi: 10.1038/nm850
Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164–72.
pubmed: 20970382
doi: 10.1016/S1474-4422(10)70254-4
Tong H, Zhang X, Meng X, Lu L, Mai D, Qu S. Simvastatin inhibits activation of NADPH oxidase/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models. Front Mol Neurosci. 2018;11:165.
pubmed: 29872377
pmcid: 5972184
doi: 10.3389/fnmol.2018.00165
Du R-W, Bu W-G. Simvastatin prevents neurodegeneration in the MPTP mouse model of Parkinson’s disease via inhibition of A1 reactive astrocytes. Neuroimmunomodulation. 2021;28(2):82–9.
pubmed: 33735898
doi: 10.1159/000513678
Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, et al. Evaluation of simvastatin as a disease-modifying treatment for patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2022;79(12):1232–41.
pubmed: 36315128
pmcid: 9623477
doi: 10.1001/jamaneurol.2022.3718